Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Narhex Declares Bankruptcy; Involved in Xi’an JV

publication date: Feb 18, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Narhex Life Sciences, an Australian pharma whose main asset was a China joint venture, has declared bankruptcy. In 2006, Narhex and China Shaanxi Dacheng International Trading Co. established a JV to develop a protease inhibitor for HIV. It also had licensed China rights to Cavidi diagnostic products, which could measure HIV viral load. From the start, the goal was to develop the products for use in China. The JV, which was called Xi’an Hex Life Sciences Co., was supported by the Xi’an High Tech Authority. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...